Aarti Pharmalabs' Q1 FY 2026-27 Quarterly Results
- 08 Aug 2026
Result Summary
- Aarti Pharmalabs Ltd reported a 9.2% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 38.3%.
- Its expenses for the quarter were down by 14.0% QoQ and up 38.1% YoY.
- The net profit increased 24.6% QoQ and increased 53.8% YoY.
- The earnings per share (EPS) of Aarti Pharmalabs Ltd stood at 8.39 during Q1 FY 2026-27.
Financial Statments for Q1 FY 2026-27
(₹ crores) | Q1FY27 | Q4FY26 | Q1FY26 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 536.25 | 590.70 | 387.79 | -9.2% | 38.3% |
Total Expenses | 442.60 | 514.53 | 320.53 | -14.0% | 38.1% |
Profit Before Tax | 93.65 | 76.17 | 67.25 | 22.9% | 39.3% |
Tax | 24.92 | 20.55 | 15.95 | 21.3% | 56.2% |
Profit After Tax | 76.14 | 61.12 | 49.50 | 24.6% | 53.8% |
Earnings Per Share | 8.39 | 6.74 | 5.46 | 24.5% | 53.7% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Aarti Pharmalabs Ltd is a company operating within the pharmaceutical industry, focusing on the production and supply of active pharmaceutical ingredients (APIs) and intermediates. The company is known for its extensive portfolio of high-quality chemical products used in the healthcare sector. Aarti Pharmalabs has built a reputation for innovation and reliability in the pharmaceutical supply chain. As of the latest available data, there are no specific major recent developments to report. However, the company continues to play a significant role in the pharmaceutical manufacturing industry, contributing to the availability of essential medications and compounds.
Revenue
In the first quarter of FY27, Aarti Pharmalabs Ltd reported a total income of ₹536.25 crores. This represents a decline of 9.2% compared to the previous quarter (Q4FY26), where the total income was ₹590.70 crores. However, when compared to the same quarter in the previous year (Q1FY26), the total income shows a significant increase of 38.3% from ₹387.79 crores. The year-over-year growth indicates an upward trajectory in revenue generation compared to the prior year, despite the recent quarter-over-quarter decline.
Profitability
During the first quarter of FY27, Aarti Pharmalabs Ltd achieved a Profit Before Tax (PBT) of ₹93.65 crores, marking a 22.9% increase from the ₹76.17 crores recorded in Q4FY26. Compared to Q1FY26, where the PBT was ₹67.25 crores, there is a year-over-year growth of 39.3%. The Profit After Tax (PAT) for Q1FY27 stood at ₹76.14 crores, which is a 24.6% increase from the previous quarter's PAT of ₹61.12 crores and a substantial 53.8% increase from the ₹49.50 crores reported in Q1FY26. Additionally, the Earnings Per Share (EPS) for Q1FY27 was ₹8.39, reflecting a quarter-over-quarter increase of 24.5% from ₹6.74 and a year-over-year increase of 53.7% from ₹5.46.
Operating Metrics
The total expenses for Aarti Pharmalabs Ltd in Q1FY27 were ₹442.60 crores, showing a quarter-over-quarter decrease of 14.0% from ₹514.53 crores in Q4FY26. Year-over-year, the expenses increased by 38.1% from ₹320.53 crores in Q1FY26. The tax expense for Q1FY27 was ₹24.92 crores, which is a 21.3% increase from ₹20.55 crores in Q4FY26 and a 56.2% increase from ₹15.95 crores in Q1FY26. These metrics highlight changes in the operational cost structure over the different periods, reflecting the company's financial management and tax obligations.
FAQs
Aarti Pharmalabs Ltd announced its Q1 FY 2026-27 results on 8 August, 2026.
Aarti Pharmalabs Ltd quarterly results refer to the company’s financial performance over a three-month period, including key metrics like revenue, net profit, earnings per share (EPS), and margin performance.
Key highlights of Aarti Pharmalabs Ltd Q1 FY 2026-27 results include:
- Revenue: ₹536.25 crore
- Net Profit: ₹76.14 crore
- EBITDA: ₹136.56 crore
- Year-over-Year Growth: 38.3%
- Quarter-over-Quarter Growth: -9.2%
Aarti Pharmalabs Ltd reported a net profit of ₹76.14 crore in Q1 FY 2026-27, reflecting a 53.8% year-over-year growth.
Aarti Pharmalabs Ltd posted a revenue of ₹536.25 crore in Q1 FY 2026-27.